Vanguard National Trust
NTLA icon

Vanguard National Trust’s Intellia Therapeutics NTLA Stock Holding History

Vanguard National Trust’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.1K Hold
597
– – ﹤0.01% 600
2026
Q1 		$7.65K Buy
+597
New +$7.61K ﹤0.01% 572

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Vanguard National Trust's NTLA Position: Q2 2026 in Review

Vanguard National Trust held its Intellia Therapeutics (NTLA) position steady in Q2 2026 at 597 shares worth $10.1K. The position accounts for ﹤0.01% of the portfolio, ranked #600.

Vanguard National Trust first reported a position in NTLA in Q1 2026 and has held it in 2 quarters since. 325 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Vanguard National Trust held 597 shares of Intellia Therapeutics worth $10.1K as of Q2 2026.
  • Vanguard National Trust left its Intellia Therapeutics share count unchanged in Q2 2026.
  • Intellia Therapeutics made up ﹤0.01% of Vanguard National Trust's portfolio in Q2 2026, its #600 holding.
  • Vanguard National Trust first reported a position in Intellia Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 325 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Vanguard National Trust's 13F filing for Q2 2026, filed 13 Aug 2026.